title: Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs.
authors.affiliation: BMJ.
authors.forename: Zosia
authors.initials: Z
authors.lastname: Kmietowicz
mesh_terms: D003257:Consumer Product Safety / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D005607:Fraud / Q000331:legislation & jurisprudence*; D006801:Humans; D007555:Isoxazoles; D040541:Marketing / Q000191:economics / Q000331:legislation & jurisprudence*; D020097:Natriuretic Peptide, Brain; D000068882:Paliperidone Palmitate; D011743:Pyrimidines; D018967:Risperidone; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007555:Isoxazoles; D011743:Pyrimidines; D020097:Natriuretic Peptide, Brain; D018967:Risperidone; D000068882:Paliperidone Palmitate